| News

Innosuisse funding new RocketVax coronavirus vaccine

16.04.2021

Leading Swiss experts in immunology and virology have joined forces in the Basel-based startup RocketVax with the aim of developing a next-generation coronavirus vaccine. The first six months of development work was funded by Innosuisse to the tune of 1.2 million Swiss francs.

Founded in the summer of 2020, RocketVax is a startup that, according to information from the company itself, is developing second-generation coronavirus vaccines. Vector vaccines are designed to attack the virus in more comprehensive fashion and work more effectively against mutations than is the case for the vaccines developed so far. The first project phase lasting six months was funded by Innosuisse to the tune of 1.2 million Swiss francs.

RocketVax is a subsidiary of Swiss Rockets AG, a startup incubator and accelerator. The company is based on the collaboration between Swiss Rockets, Gigabases Switzerland AG, which is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH), and University Hospital Basel in addition to ETH Zurich itself, the University of Zurich (UZH), University of Basel and the Swiss Tropical and Public Health Institute.

“The support provided by Innosuisse, the Swiss Innovation Agency, confirms the validity of our innovative research approach”, explains Dr. Vladimir Cmilijanovic, founder and CEO of Swiss Rockets and RocketVax, in a press release. “For the team, this support represents an important milestone on the road to successfully achieving the project’s aim of creating a next-generation SARS-CoV-2 vaccine”, he adds.

The RocketVax vaccine, known as RVX-13, uses coronavirus-based vectors. It is above all characterized by the fact that it contains all SARS-CoV-2 structural proteins, which differs from first-generation vaccines that only target the spike protein. However, these are unable to reproduce, meaning that they are not infectious. The aim here is to provoke a much broader antibody reaction and to reduce risks connected with viral escape mechanisms.

A digital DNA-designing platform ensures a straightforward design process and efficient production of new vaccine vectors, the press release explains. Moreover, the process can be quickly adapted to viral mutations. Allergic reactions are avoided, while the vaccine remains stable for longer at room temperature.

An animal model proof of concept is now imminent. Processes linked to the good manufacturing practice (GMP) quality assurance system in addition to scaleup activities are on the agenda for the next eight months. Thereafter, preclinical and clinical trials are set to follow.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
For Swiss startups, China might be closer than it seems
Basel Area Business & Innovation, Invest

For Swiss startups, China might be closer than it seems

China wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
1 2 3 46

Do you have a question? We'd like to hear from you.